. Author manuscript; available in PMC: 2010 Jul 1.

Published in final edited form as: Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):98–109.

Table 5.

Clinical outcomes in 6 patients with active sarcoidosis.

No.	Follow-up interval (weeks)	Disease activity	Changes in treatment	Other new system involvement
1	16	Inactive	Continue methotrexate therapy	No
2	20	Active	Discontinue methotrexate due to side effect	No
			Increase dose of prednisone
3	57	Inactive	Continue methotrexate	No
			Discontinue prednisone
4	29	Inactive	Discontinue treatment	No
5	32	Inactive	Continue methotrexate	No
			Taper off prednisone
6	24	Active	Increase dose of methotrexate	No

Note. Clinical outcomes at follow-up visit 16-57 weeks after the last measurement.